



**Carter BloodCare**

We save lives by making transfusion possible.

**To:** Transfusion Services Managers  
**From:** Hospital Relations Department  
**Date:** December 16, 2015  
**Re:** Additional Sample Required for Daratumumab Therapy

Treatment for Multiple Myeloma that includes the drug daratumumab (DARA) causes interference with serological testing resulting in panagglutination. Due to the interference, samples from patients on this drug therapy will be reflexed for molecular testing that will require an additional 3-7ml EDTA sample.

Please include the additional sample if you are aware that the patient is receiving daratumumab.